# ProofLink — Final Quality Check
**Reviewer:** Final Quality Review (Senior)
**Date:** March 20, 2026
**Documents reviewed:**
- `/home/akash/PROJECTS/prooflink/strategy/pitch_deck_v2.md`
- `/home/akash/PROJECTS/prooflink/reviews/strategy_review.md`
- `/home/akash/PROJECTS/prooflink/EXECUTIVE_SUMMARY.md`

---

## 1. Does pitch_deck_v2.md Address ALL Criticisms from strategy_review.md?

### Criticisms Addressed

**Pricing inconsistency (CRITICAL — strategy_review.md section 2, line 77):** RESOLVED.
The $0.01/tx flat fee is eliminated. The deck now uses a consistent bps model (30 bps Starter / 15 bps Growth / 5-10 bps Enterprise) with subscription tiers stacked on top. The pre-pitch checklist explicitly calls out the old model as dead. This was the most dangerous inconsistency and it is fixed.

**$600M annualized x402 figure (strategy_review.md Slide 2 note):** RESOLVED.
The figure is removed. Slide 2 honestly states "$28K/day actual commerce, rest is testing/micro-transactions." The honest framing is now in place.

**Unit economics missing (strategy_review.md section 2, "What's missing"):** RESOLVED.
Slide 9 now includes a full COGS table (Notabene, TRM Labs, Chainalysis, infrastructure) and explicit gross margin calculations at the transaction level (>99%) and at $10M/month volume (>98%). This is among the stronger additions in v2.

**TRM Labs absent from competitive matrix (strategy_review.md section 5):** RESOLVED.
TRM Labs is in the matrix (Slide 5) with pricing cited ($100K+/yr), architectural comparison, and a dedicated paragraph calling them "the closest architectural threat" and a "potential acquirer, not a direct competitor at our market tier." This is handled candidly.

**Notabene absent from competitive matrix:** RESOLVED.
Notabene is in the matrix with the correct characterization (Travel Rule only, no payments).

**The Coinbase question unanswered (strategy_review.md section 3):** RESOLVED.
Slide 15 is dedicated entirely to this question with three specific differentiators: cross-protocol scope, ecosystem coverage outside Coinbase's perimeter, and the KYA open standard lock-in. The honest acknowledgment of the risk mitigation timeline is appropriate.

**"What happens when a check fails" — missing failure flow (strategy_review.md Slide 6 note):** RESOLVED.
Slide 6 now explicitly covers the failure path: payment blocked, structured rejection with reason code, CFO notification, SAR queue. This is a meaningful improvement.

**GTM weakness — LinkedIn/content marketing (strategy_review.md section 2):** RESOLVED.
Slide 10 explicitly says "NOT doing: Cold LinkedIn outreach to Fortune 500 CFOs." The replacement strategy ranks hackathons first, then free-tier GitHub distribution, then compliance community events (ACAMS, BSA Coalition), then Big 4 partner channels, then direct outreach to existing Request Finance customers. This is the correct order for a 2-person team.

**Phase 2 target: Fortune 500 (strategy_review.md Slide 10 note):** RESOLVED.
The deck now targets mid-market enterprises with deployed AI agents (60-90 day sales cycles), not Fortune 500 (12-18 months). The correction is explicit and noted.

**Slide 11 placeholders (strategy_review.md, CRITICAL):** PARTIALLY RESOLVED. See section 2 below.

**Team slide catastrophically thin (strategy_review.md, CRITICAL):** PARTIALLY RESOLVED. See section 2 below.

**$150T cross-border figure removed (strategy_review.md Slide 4):** RESOLVED.
The TAM is now framed as a revenue opportunity at bps-of-volume, not raw payment volume. The $150T figure is gone.

**Superfluid/Sablier removed from competitive matrix:** Cannot confirm — they do not appear in v2. Assumed resolved.

**Regulatory engagement narrative (strategy_review.md section 5):** RESOLVED in a bounded way.
The deck does not falsely claim regulatory relationships. It explicitly states (Appendix C) that no regulatory contact has been made yet, names a 90-day plan for comment letter submission, and frames the KYA spec submission to W3C CG as the start of the standards process. This is honest without being self-defeating.

**Stress test for slow agent adoption:** RESOLVED.
Appendix A is a dedicated scenario analysis for A2A taking 3 years. The conclusion (H2H alone supports $2-3M ARR by Year 2) is credible and the agent economy is correctly reframed as upside, not a survival dependency.

**Regulatory non-enforcement scenario:** RESOLVED.
Appendix B covers this explicitly with four independent reasons ProofLink still creates value without regulatory mandate for agents.

**Chainalysis vendor lock-in question:** RESOLVED.
Appendix C answers this directly: free tier uses the public Chainalysis SDN API (no contract required), paid tiers use TRM Labs and ChainAware as primary sources. The dependency is eliminated as a kill risk.

**ERC-8004 security model (malicious agent):** RESOLVED.
Appendix C answers this: registration is permissionless but KYA verification is not; a fake ERC-8004 credential fails verification because the human principal cannot be verified independently.

**Anticipated VC questions unanswered:** RESOLVED.
Appendix C systematically answers every hard question from the original review.

**TAM stated as volume not revenue (strategy_review.md Slide 4):** RESOLVED.
TAM is now "$339M ARR addressable today" (15 bps on $226B annualized B2B volume). Correct framing.

**Exit narrative should close the deck:** RESOLVED.
Slide 16 is now dedicated to the acquisition narrative with a comparison table of five potential acquirers and explicit BVNK/Bridge comparables.

---

### Criticisms NOT Fully Addressed

**1. Slide 11 — placeholders remain (CRITICAL, UNRESOLVED).**
The deck still contains "[INSERT REAL METRICS: transactions processed, API calls, developer signups, GitHub stars]" and "[INSERT: hackathon results, demo links]" and "[INSERT: design partner name and LOI status]." The pre-pitch checklist at the top of the deck acknowledges this is unfilled. The checklist's existence is a sign of intellectual honesty but does not resolve the underlying gap. This slide cannot go to any investor in this state. The 90-day execution plan that follows is strong, but it substitutes ambition for evidence.

**2. Cofounder unnamed (CRITICAL, UNRESOLVED).**
Slide 13 still reads "[Cofounder Name — FILL BEFORE ANY PITCH]" with bracketed credential placeholders. A team slide with a placeholder cofounder is worse than having no cofounder listed at all — it tells the investor that the founder knows this is a problem and still did not fix it before sending the deck. The pre-pitch checklist acknowledges this. It does not fix it.

**3. Compliance advisor unnamed (HIGH, UNRESOLVED).**
Slide 13 lists "[Compliance Advisor] — [Former FinCEN/FATF official...]" as a placeholder. The review rated this as converting a "two-person startup to a team with domain authority." The placeholder provides the framework but zero credibility. The deck cannot go to investors in this state.

**4. Legal opinion on VASP/MSB classification (CRITICAL, UNRESOLVED).**
The pre-pitch checklist lists this as mandatory item 3. It is not in the deck because it does not yet exist. The checklist at the top of the deck explicitly warns not to pitch without it. This is the correct treatment but the underlying document is still missing.

**5. Design partner LOI (CRITICAL, UNRESOLVED).**
Pre-pitch checklist item 5 is not checked. No design partner is named anywhere in the deck. Same treatment as above — acknowledged but unresolved.

---

## 2. Remaining Inconsistencies

### Between pitch_deck_v2.md and EXECUTIVE_SUMMARY.md

**Inconsistency 1: Revenue trajectory numbers.**
`EXECUTIVE_SUMMARY.md` (The Product section): "Year 1: $550K ARR | Year 2: $5.5M ARR | Year 3: $23M ARR"
`pitch_deck_v2.md` (Slide 4, SOM): "Year 1: $300K-$550K ARR"
`pitch_deck_v2.md` (Slide 14, Series A target): "$1M-$2M ARR" at 18 months
`pitch_deck_v2.md` (Appendix A): "Year 2: $2M-$3M ARR"

The executive summary still uses the v1 revenue figures ($550K / $5.5M / $23M) while the pitch deck v2 has been revised downward for Year 1 ($300K-$550K range) and Year 2 ($2M-$3M). The executive summary is out of sync on Year 2 ($5.5M vs. $2M-$3M) and Year 3 ($23M — not updated to reflect the more conservative trajectory). A VC who reads both documents will see different numbers at the same milestone. This is a credibility problem.

**Inconsistency 2: Pre-seed raise range.**
`EXECUTIVE_SUMMARY.md` (What We Need): "$500K-$2M"
`pitch_deck_v2.md` (Slide 14): "$750K-$1.5M"

These ranges overlap but are not identical. Both documents will be in investor hands simultaneously. The ranges should be identical.

**Inconsistency 3: Phase 3 timeline.**
`EXECUTIVE_SUMMARY.md` (The Product): "Phase 3 (Q1 2027): Agent-to-Agent"
`pitch_deck_v2.md` (Slide 10): "Phase 3 (2027+): Agent-to-Agent Economy"

The executive summary says Q1 2027. The pitch deck says 2027+. The strategy review specifically criticized the Q1 2027 A2A timeline as "aggressive to the point of damaging credibility." The deck v2 softened this to "2027+" but the executive summary still shows Q1 2027. An informed VC will ask which document is current.

**Inconsistency 4: Design partner threshold.**
`EXECUTIVE_SUMMARY.md` (Team Gaps): "One mid-market company processing $5M+/month in cross-border stablecoin payments"
`pitch_deck_v2.md` (Pre-pitch checklist): "at least one mid-market crypto company ($10M+ cross-border payables)"

$5M/month annualizes to $60M/year. $10M+ in the deck could mean annual or monthly. These describe different-sized targets and will confuse anyone reading both.

**Inconsistency 5: Series A KYA adoption metric.**
`pitch_deck_v2.md` (Slide 14): "KYA standard adopted by at least one major protocol"
`EXECUTIVE_SUMMARY.md` (18-month target): "KYA standard referenced in regulatory guidance"

"Adopted by one major protocol" and "referenced in regulatory guidance" are different milestones with different probability distributions. Protocol adoption in 18 months is plausible. Regulatory guidance citation in 18 months is ambitious. These should align.

### Within pitch_deck_v2.md

**Internal inconsistency 1: Slide 5 pricing for ProofLink.**
The competitive matrix (Slide 5) shows ProofLink's pricing as "$499/mo + 15bps." This represents only the Business tier. A reader of Slide 5 without reading Slide 9 will not know about the Free, Developer, or Enterprise tiers, or the volume-tiered bps structure (30 bps Starter / 15 bps Growth / 5-10 bps Enterprise). A VC will flag this in due diligence as inconsistent. The matrix entry should show "$0-$2,000+/mo + 5-30bps" or link explicitly to Slide 9.

**Internal inconsistency 2: Month 12 volume target vs. Year 1 ARR.**
Slide 9 (Unit Economics) models "$10M/month platform volume (Month 12 target)" generating "$40K-$55K/month" revenue, which annualizes to $480K-$660K ARR. Slide 4 (SOM) shows "$300K-$550K ARR" for Year 1. The unit economics model and the SOM range do not align — the model produces $480K-$660K while the SOM shows $300K-$550K. The $10M/month Month 12 assumption is also aggressive for a team starting from zero.

---

## 3. Is the Pricing Model Now Consistent?

**Within the deck: Yes, with one caveat.**
The bps model is used consistently throughout Slide 9. The Slide 5 matrix entry is a simplified version (only showing one tier) but does not contradict the model. The v1 $0.01/tx flat fee is gone everywhere in the deck. The pre-pitch checklist explicitly states it is dead.

**Between the deck and executive summary: Mostly, with drift.**
The executive summary (The Product section) says "transaction fees (5-30 bps) + subscriptions ($99-$2,000+/month)" — this matches the deck's structure exactly. No contradiction. The revenue trajectory numbers are different (see Inconsistency 1 above) but that is a separate issue from the fee model itself.

**Verdict: The pricing model is internally consistent within the deck. The executive summary still carries the old $550K Year 1 / $5.5M Year 2 ARR projections, which imply the higher end of the pricing assumptions. These should be updated to match the deck's conservative range.**

---

## 4. Is the Team Slide Improved?

**Marginally. Not sufficiently for an investor meeting.**

Improvements over v1:
- The CEO credentials are now fully articulated: IIT Patna, CERN GSoC, vLLM contributor, specific work on ProofLink Engine and KYA standard, agent behavioral analysis described as a data moat.
- The "Why us" section exists and provides a specific answer (technical depth + insider knowledge of Request Finance gaps + compensating advisors).
- The honest gap acknowledgment is present and appropriately framed: "Neither founder has a compliance/regulatory background. This is why the compliance advisory board is critical."
- The advisor framework is defined with specific profile types requested (former FinCEN/FATF, ACAMS board member).

What is still missing:
- The cofounder is still unnamed. The placeholder "[Cofounder Name — FILL BEFORE ANY PITCH]" is present with all credentials still in brackets.
- No advisor is named. The advisor section lists "[Compliance Advisor] — [Former FinCEN/FATF official...]" with no actual person named.

The team slide improvement is structural but not substantive. The framework for what the slide should say is correct. The actual content — two real humans with verifiable credentials — is still absent. A slide that says "we know we need a compliance advisor" is not the same as having one.

**Honest assessment: The team slide template is investor-ready. The team slide content is not.**

---

## 5. Are the Volume Numbers Honest?

**Yes. This is one of the clearest improvements in v2.**

- The $600M annualized x402 figure is gone.
- x402 volume is stated as "75M+ transactions in 30 days — but real commerce volume is still early-stage ($28K/day actual commerce, rest is testing/micro-transactions)." This is the honest number.
- Appendix A explicitly models a scenario where A2A stays under $1M/day through 2027.
- Appendix B models what happens if regulators exempt agent transactions from Travel Rule requirements.
- The SOM is $50M-$100M cumulative volume in Year 1, not the $2B/month run-rate implied by v1's Year 2 projection.
- The Year 2 ARR in the deck is $2M-$3M (Appendix A), not the $5.5M in the executive summary — though this discrepancy between the two documents needs to be resolved.

The "73% of CFOs evaluating crypto payment options" (from strategy_review.md as a flagged unsupported claim) does not appear in the deck v2. The "80% of Fortune 500 have active AI agents in production" claim is also gone. Both were correctly removed.

**One remaining honesty concern:** The SOM section on Slide 4 targets "$500M-$2B monthly volume through the platform by Year 3." Year 3 corresponds to the Phase 3 Agent-to-Agent phase. The deck correctly says A2A at scale is a 2027-2028 story, but the Year 3 volume figure implicitly depends on A2A materializing. If A2A is delayed (Appendix A scenario), the Year 3 volume figure should be revisited. This is not a fatal inconsistency — it is flagged in the appendix — but a VC who builds a bottoms-up model will catch it.

---

## 6. Does It Pass the "Tough VC Partner" Test?

**At a top-tier pre-seed fund with compliance thesis: Conditional pass on thesis. Hard fail on team and traction.**

What will survive a tough VC partner meeting:
- The regulatory tailwinds section (Slide 3) is tight, sourced, and well-reasoned. The FATF enforcement timing argument is credible.
- The competitive whitespace analysis is genuine intellectual work. TRM Labs is now in the matrix and characterized accurately.
- The Coinbase question (Slide 15) is answered with three specific, non-hand-wavy differentiators.
- The unit economics (Slide 9) are defensible. Gross margin above 98% at scale is credible for a middleware product.
- The acquisition narrative (Slide 16) is the strongest closing argument available — two comparable exits in the same category in 12 months is exceptional timing.
- The appendix stress tests show the founders have thought about downside scenarios. VCs notice this.

What will not survive a tough VC partner meeting:
- "Who is your cofounder?" — the answer is still a placeholder.
- "Who is your compliance advisor?" — the answer is still a placeholder.
- "What are your current metrics?" — the answer is still "[INSERT REAL METRICS]."
- "Do you have a legal opinion on your MSB classification?" — the answer is no.
- "Do you have a design partner?" — the answer is no.

A Haun Ventures or Dragonfly partner who likes the thesis will do one thing before scheduling a second meeting: check whether the five mandatory checklist items are complete. Three of the five (team, legal opinion, design partner) are still open. The other two (pricing and Slide 11 plan) are addressed structurally but not with real data.

**The deck is fundable in 30-60 days if the checklist items are closed. It is not fundable today.**

---

## Cross-Document Consistency Summary

| Item | pitch_deck_v2.md | EXECUTIVE_SUMMARY.md | Consistent? |
|------|-----------------|---------------------|-------------|
| Year 1 ARR | $300K-$550K | $550K | Partial — exec summary shows upper bound only |
| Year 2 ARR | $2M-$3M (Appendix A) | $5.5M | **NO — $5.5M is the old v1 figure** |
| Year 3 ARR | Not explicitly stated in main deck | $23M | Cannot confirm alignment |
| Pre-seed raise | $750K-$1.5M | $500K-$2M | Partial — different ranges |
| Phase 3 timing | 2027+ | Q1 2027 | **NO — exec summary is more aggressive** |
| Pricing model | 5-30 bps + $0-$2K+/mo sub | 5-30 bps + $99-$2K+/mo | Minor — exec summary missing Free tier |
| x402 volume | $28K/day real commerce | $28K/day | YES |
| Design partner threshold | $10M+ cross-border payables | $5M+/month | Ambiguous — different units |
| Series A KYA metric | Protocol adoption | Regulatory citation | **NO — different milestones** |
| VASP/MSB legal opinion | Required, not yet obtained | Required, not yet obtained | YES |

---

## VERDICT

**FAIL**

The deck is significantly improved from v1. The thesis is coherent, the pricing model is internally consistent, the volume numbers are honest, the competitive analysis is complete, all anticipated VC questions are pre-answered in the appendix, and the downside scenarios are stress-tested. These are genuine improvements.

The deck fails to meet investor-readiness for one reason: **the five mandatory checklist items at the top of the deck are not complete.** The founders correctly identified these requirements in the pre-pitch checklist. None of the five are resolved:

1. Slide 11 still has placeholders — real metrics or a signed LOI must replace them
2. The cofounder is unnamed with bracketed credentials
3. The legal VASP/MSB opinion does not exist
4. The pricing model is consistent within the deck but the executive summary carries the old revenue projections
5. No design partner LOI exists

Additionally, the executive summary and pitch deck are not in sync on three material points (Year 2 ARR, Phase 3 timing, Series A KYA metric). Both documents will be in the same investor's hands. The discrepancies will be noticed.

---

## Items to Fix Before First Pitch (Prioritized)

**Must fix — will kill the pitch if not resolved:**

1. **Name the cofounder with full credentials on Slide 13.** Full name, specific role at Request Finance, verifiable technical contribution, any compliance/fintech background. No placeholder. No approximation.

2. **Name at least one compliance advisor on Slide 13.** A former FinCEN official, FATF working group member, or CCO at a regulated crypto firm. A live human with a LinkedIn profile who has agreed to be named.

3. **Obtain the VASP/MSB legal opinion.** $5-15K to a fintech attorney. Redacted version available for investors. This removes the biggest existential risk from the room.

4. **Secure one design partner LOI.** One company processing $10M+/year in cross-border stablecoin payments, willing to be named. Replace Slide 11 placeholder with their name and the pilot terms.

5. **Replace Slide 11 placeholders with real data.** Even minimal data — GitHub stars, API calls in a demo, developer signups, hackathon results — is better than "[INSERT REAL METRICS]." If no data exists, the 90-day plan is an acceptable placeholder only if all other checklist items are complete.

**Must fix — will be caught in due diligence:**

6. **Update EXECUTIVE_SUMMARY.md to match pitch_deck_v2.md.** Specifically: Year 2 ARR ($2M-$3M, not $5.5M), Phase 3 timing (2027+, not Q1 2027), pre-seed raise range ($750K-$1.5M to match the deck), Series A KYA metric (protocol adoption, not regulatory citation).

7. **Reconcile Slide 4 SOM with Slide 9 unit economics.** The Month 12 model generates $480K-$660K ARR; the SOM shows $300K-$550K. Either the model assumptions need to change or the SOM range needs to expand.

8. **Align Slide 5 matrix entry with Slide 9 pricing.** The matrix shows only the Business tier pricing. Add a note or range that reflects the full pricing structure.

**Fix before Series A (not blocking pre-seed):**

9. **Year 3 volume target in Slide 4 SOM.** The "$500M-$2B monthly volume by Year 3" figure implicitly assumes A2A materializes. If the Appendix A slow-adoption scenario is real, this number needs a scenario-based range.

10. **Design partner threshold alignment.** Decide whether the target is "$5M+/month" (executive summary) or "$10M+ cross-border payables/year" (pitch deck) and use identical language across all materials.

---

*Final Quality Review — March 20, 2026*
*Documents reviewed: pitch_deck_v2.md, strategy_review.md, EXECUTIVE_SUMMARY.md*
